We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 24, 2021

Lenalidomide Before and After Autologous SCT in Myeloma Patients of All Ages



Additional Info

Lenalidomide Before and After Autologous Stem Cell Transplantation for Transplant-Eligible Patients of All Ages in the Randomized, Phase III, Myeloma XI Trial
Haematologica 2021 Jul 01;106(7)1957-1967, GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, A Waterhouse, JR Jones, B Kishore, M Garg, CD Williams, K Karunanithi, J Lindsay, D Allotey, S Shafeek, MW Jenner, G Cook, NH Russell, MF Kaiser, MT Drayson, RG Owen, WM Gregory, GJ Morgan, UNHO Clinical Studies Group

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading